2025. Safety Profile of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Integrated Data used in the US Prescribing Information. SKIN The Journal of Cutaneous Medicine. 9, 2 (Apr. 2025), s572. DOI:https://doi.org/10.25251/skin.10.supp.572.